{"title": "The top 15 biopharma licensing deals of 2020", "author": "Phil Taylor", "url": "https://www.fiercebiotech.com/special-report/top-15-biopharma-licensing-deals-2020", "hostname": "fiercebiotech.com", "description": "What were the most sought-after assets when biopharma companies went shopping for licensing opportunities last year? Oncology, and more specifically immuno-oncology programs, dominated our list of the highest-value deals of 2020. Cancer-related assets accounted for more than half (eight) of the top 15, with four in the cancer immunotherapy area, demonstrating that biopharma's appetite for this area is far from sated. Collectively, the cancer deals had a value (biobucks included) of almost $24 billion out of a total of just over $40 billion overall. | Oncology, specifically immuno-oncology, was the dominant theme in biopharma licensing last year, as cancer drugs accounted for half of the top deals.", "sitename": "FierceBiotech", "date": "2021-04-27", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}